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Abstract: Sustained endoplasmic reticular stress (ERS) is implicated in aggressive metastasis of 
cancer cells and increased tumor cell proliferation. Cancer cells activate the unfolded protein 
response (UPR), which aids in cellular survival and adaptation to harsh conditions. Inhibition of 
apoptosis, in contrast, is a mechanism adopted by cancer cells with the help of the inhibitor of an 
apoptosis (IAP) class of proteins such as Survivin to evade cell death and gain a proliferative 
advantage. In this study, we aimed to reveal the interrelation between ERS and Survivin. We 
initially verified the expression of Survivin in Winnie (a mouse model of chronic ERS) colon tissues 
by using immunohistochemistry (IHC) and immunofluorescence (IF) in comparison with wild type 
Blk6 mice. Additionally, we isolated the goblet cells and determined the expression of Survivin by 
IF and protein validation. Tunicamycin was utilized at a concentration of 10 µg/mL to induce ERS 
in the LS174T cell line and the gene expression of the ERS markers was measured. This was followed 
by determination of inflammatory cytokines. Inhibition of ERS was carried out by 4Phenyl Butyric 
acid (4PBA) at a concentration of 10 mM to assess whether there was a reciprocation effect. The 
downstream cell death assays including caspase 3/7, Annexin V, and poly(ADP-ribose) polymerase 
(PARP) cleavage were evaluated in the presence of ERS and absence of ERS, which was followed by 
a proliferative assay (EdU click) with and without ERS. Correspondingly, we inhibited Survivin by 
YM155 at a concentration of 100 nM and observed the succeeding ERS markers and inflammatory 
markers. We also verified the caspase 3/7 assay. Our results demonstrate that ERS inhibition not 
only significantly reduced the UPR genes (Grp78, ATF6, PERKandXBP1) along with Survivin but 
also downregulated the inflammatory markers such as IL8, IL4, and IL6, which suggests a positive 
correlation between ERS and the inhibition of apoptosis. Furthermore, we provided evidence that 
ERS inhibition promoted apoptosis in LS174T cells and shortened the proliferation rate. Moreover, 
Survivin inhibition by YM155 led to a comparable effect as that of ERS inhibition, which includes 
attenuation of ERS genes and inflammatory markers as well as the promotion of programmed cell 
death via the caspase 3/7 pathway. Together, our results propose the interrelation between ERS and 
inhibition of apoptosis assigning a molecular and therapeutic target for cancer treatment. 
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1. Introduction 
The disruption of endoplasmic reticular homeostasis by various physiological stimuli leads to 
the accumulation of misfolded proteins. This phenomenon is called endoplasmic reticular stress 
(ERS), which, in turn, induces a coordinated program called an unfolded protein response [1]. The 
unfolded protein response (UPR) triggered by ERS serves as an adaptive mechanism to protect the 
cell from stress and restore endoplasmic reticulum (ER) homeostasis. An increase in ERS initiates the 
UPR, which results in programmed cell death or apoptosis. In conditions such as cancer, ERS initiates 
an unfavorable micro-environment that may include low pH and hypoxia, which leads to the 
accumulation of misfolded proteins. Under normal cellular conditions, the above factors collectively 
lead to apoptosis to ameliorate ER stress and reinstate homeostasis. In cancer, numerous mechanisms 
have evolved to circumvent environmental stress and evade cell death [2,3]. 
ER chaperones are the group of proteins typically involved in shuttling proteins into ER and 
modifying with N-linked glycans, which was folded into the appropriate secondary and tertiary 
structures. These are stabilized by disulfide bonds and, in many cases, are assembled into multimeric 
complexes [4]. Inhibition of ER chaperone proteins that aid in correct protein folding has been 
suggested as a therapeutic approach in cancer treatment, which targets pro-survival pathway 
inhibition and subsequent initiation of cancer cell death [5]. Apoptosis is dependent on the triggering 
of caspases and a special class of proteins known as an inhibitor of apoptosis proteins (IAPs), which 
negatively regulates caspases and apoptosis [6]. Numerous cellular processes are controlled by IAPs. 
In cancers, IAPs either directly or indirectly contribute to tumorigenesis through disease initiation, 
progression, cellular proliferation, and tumor preservation. Thus, IAPs are gaining clinical interest 
for their role in therapeutics as tumor markers. 
Survivin is one of the IAP that protects cells from apoptosis. Survivin was reported to act as a 
‘gatekeeper’ at the G2-M boundary of the cell cycle and resides between the nucleus and cytoplasm, 
which binds to caspase activation involved in apoptosis [7]. Survivin is highly organ-specific and 
tissue-specific and is linked to several processes such as angiogenesis. The stress response and p53 
linkage as Survivin was said to regulate p53 [8]. Survivin is responsible for aggressiveness cellular 
proliferation in colorectal cancers (CRC) and its inhibition via PARP6 resulted in the reduction of 
tumors [9]. This highlights an essential role for survivin as a critical regulator of tumorigenesis and 
is, therefore, amendable to therapeutic intervention in the treatment of cancer progression. 
ER stress in situ often correlates with advanced-stage disease and chemoresistance. The ability 
to tolerate persistent ER stress enhances cancer cell survival, angiogenesis, metastatic capacity, drug 
resistance, and immune-suppression [10]. ERS inhibition has gained attention in establishing a 
therapeutic approach to treat various disease states. ERS inhibitors including benzodiazepines, 
baicalein, 1-deoxymannojirimycin hydrochloride, and others targeting ERS genes such as CHOP and 
ER alpha-mannosidase were employed in various cell lines including stem cells and progenitor cells 
to bring down the levels of reactive oxygen species (ROS) and chaperones in order to establish a 
therapeutic role [11]. ER misfolding defects are associated with aggressive tumor growth and, 
therefore, it is critical to understand the molecular mechanisms and regulation of the UPR. Cancer 
survival in one way depends on the UPR signaling pathways that orchestrate cellular processes such 
as apoptosis and autophagy. Pharmacological induction of ERS leads to escalation of UPR markers 
and pro-inflammatory cytokines [12]. In addition, ERS inducers such as thapsigargin in tumor mice 
aggravated the tumors, which form a link between ERS and cancer progression. However, there was 
no clear link between ERS and IAP proteins such as Survivin and, hence, we decided to investigate 
the relationship between these two mechanisms and subsequent downstream effects like 
inflammation, apoptosis, and proliferation. 
In the present study, we determined the expression of Survivin in Winnie, which is a chronic 
ERS mouse model displaying severe colitis due to missense Muc2 mutations [13]. We have also 
correlated Muc2 expression with proliferation in LS174T cells since theMuc2 role was perplexing in 
the gut due toa number of studies correlating Muc2 expression with severe ERS [14] and Muc2 
positive expression, which was relatable with increased proliferation [15]. 
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Importantly, Survivin expression is a well-established event in the development of colonic 
adenocarcinoma [16]. Studies have documented Survivin translocation between the nucleus and 
cytoplasm. Its potential role as an inhibitor of apoptosis is conducted by binding to the mitochondrial 
activator of caspase and portraying it as a bridge between apoptosis and mitosis [17]. Apoptosis and 
ERS, in contrast, are responsible for the development of various diseases. The molecular link between 
ERS and apoptosis has not yet been established based on a plethora of complex events including the 
accumulation of folded proteins and hypoxia as part of the pro-survival mechanism [18]. Hence, it 
was vital to understand the link between the inhibition of apoptosis, ERS, pro-survival, proliferation, 
and cancer. 
We have shown for the first time a reciprocal relationship between ERS and Survivin through 
chemical inducers and inhibitors of ERS and Survivin activity. This relationship was also concomitant 
with cell death and the rate of cellular proliferation in the human colon cancer cell line LS174T. 
2. Materials and Methods 
2.1. Cell Culture 
The human colon cancer cell line (LS174T-ATCC® CL-188™) was cultured in Roswell Park 
Memorial Institute medium RPMI media with added L-glutamine (Life Technologies, Victoria, 
Australia) supplemented with 10% fetal bovine serum, penicillin (1000 UG/mL), and streptomycin 
(1000 U/mL) (Gibco BRL, Victoria, Australia). Cells were incubated under 37 °C and 5% CO2.After 
reaching confluency, the cells were harvested using 0.25% TrypLe express (Life Technologies, AUS). 
The detached cells were determined for the cell number and viability after washing by using the 
Countess® cell counter (Life Technologies, AUS) as per the instructions. 
2.2. Animals 
All animal experiments were approved by the Animal Ethics Committee of the University of 
Tasmania (Ethics approval number: A14095, 2017) and conducted in accordance with the Australian 
Code of Practice for Care and Use of Animals for Scientific Purposes (8th Edition 2013). All the 
animals were bought from the Cambridge farm facility (Hobart, Australia). Animal housing was 
under a 21 °C environment with a 12-h day/night cycle. All mice had continuous access to radiation-
sterilized rodent feed (Barastoc Rat and Mouse, Ridley AgProducts, Hobart, Australia) and 
autoclaved tap water ad libitum. 
2.3. Isolation of Goblet Cells 
The animals were sacrificed via CO2 asphyxiation in the morning before the abdomen was 
dissected and the colon removed. Colons were then harvested from 16 weeks, 10 Winnie 
(homozygous Muc2 mutant), and 10 wild type mice (C57BL6/J background) of both sexes, sliced 
lengthwise, and washed with ice cold phosphate buffer saline (PBS). The colons were stored on ice in 
Dulbeccos’ Modified Eagle Medium (DMEM) L-glutamine (Life Technologies) and supplemented 
with 10% fetal bovine serum (Gibco, VIC, AUS), penicillin (1000 U/mL), and streptomycin (1000 ug/L) 
(Gibco BRL, AUS) until all colons were collected. The colons were washed twice with PBS and placed 
in pre-digestion solution (liberase 0.35 mL; Hanks’ balanced salt solution HBSS). The liberase was 
prepared by utilizing 5 mg/mL of the concentration. A total of 2.3 mL of HBSS needs to be added to 
prepare the master stock and later needs to be divided into aliquots. In an individual experiment, 168 
µL of liberase from the aliquot was added into 10 mL of HBSS. The samples were incubated using 5 
mg/mL liberase in HBSS for 15 min with rocking in a 37 °C incubator, 4.5% CO2. The colon crypts 
were collected by scraping the colons (cells off from the basement membrane by using a pipette tip 
and forceps). The crypts isolated were passed through a 100 µm cell sieve. The cells were then 
subjected to a gentle spin at 3000× g, 4 °C for 5 min. The gradient assay was employed. The goblet cell 
pellet was re-suspended in freezing medium (6:3:1) Medium: Fetal bovine serum (FBS): DMEM and 
was transferred into a cryo-vial and stored for future use. 
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2.4. RNA Extraction and cDNA Conversion 
The RNeasy Mini kit was employed (Qiagen, VIC, AUS) with RNase-Free DNase set (Qiagen, 
AUS) to extract RNA from LS174T cells (3 × 105cell population). The RNA quantitative and qualitative 
analysis was performed by using an Experion automated electrophoresis system (Bio-Rad 
Laboratories, VIC, AUS) and RNA samples with an RNA quality index (RQI) >7.0 were considered 
suitable for expression analysis. The iScript cDNA synthesis kit (Bio-Rad Laboratories, AUS) was 
used to transcribe one microgram of total RNA to cDNA as per the manufacturing protocol. 
2.5. qRTPCR 
The RT-PCR was performed by using Taqman® probes (Life Technilogies, AUS) for GAPDH 
(Hs03929097_gl), ATF6 (Hs00232586_m1), XBP1 (Hs00231936_m1), GRP78 (Hs0060719_gH), CHOP 
(Hs00358796_g1), and PERK (Hs00984006_m1). The RT-reaction mixture consisted of 40 ng of cDNA, 
Taqman Fast Advanced Master mix (Life Technologies, AUS), and 1 µL of gene-specific probe/total 
volume of 20 µL. The reactions were run in duplicates on the qRT-PCR machine (StepOne Plus-Life 
Technologies, VIC, AUS).Thermo cycling conditions included 90 °C for 20 s, 40 cycles at 95 °C for 1 
s, and 60 °C for 20 s. Gene expression was quantified by using the comparative (ΔΔCT) method where 
the threshold cycle (CT) for each gene was normalized to reference gene GAPDH. 
2.6. The Assessment of Cytokines by Bioplex 
Ls174T cells were utilized for measurements of IL-8, IL-4, IL-6, and IL-10 cytokine levels. The 
cells were subjected to the corresponding treatments of tunicamycin, 4-phenylbutyric acid (4PBA) 
and YM155. The cells were cultured in 12-well cell culture plates (Greiner, VIC, AUS) and were 
seeded at a density of 3.0 × 105 cells for every well in 2.0 mL of medium and incubated overnight at 
37 °C/5% CO2 to enable the cells to adhere. Medium was replaced the following day comprising of 
the treatments: Tunicamycin (10 µg/mL in DMSO) and 4PBA (40 µg/mL) incubated for 6 h at 37 °C/5% 
CO2. After 6 h of treatment, the media from each well was collected and utilized for measuring 
cytokines by utilizing the Bio-Plex® Pro human cytokine assay kit (Bio-Rad®), which is indicated by 
the manufacturer protocol. Additionally, 50 µL of cytokine beads were added to the 96-well plate 
and incubated for 30 min before washing twice with wash buffer. At that point, 50 µL of every 
standard including blank tests were added to the individual wells and incubated at room 
temperature on a shaker at 850 rpm for 30 min. Post incubation, the wells were washed thrice and 25 
µL of detection antibody was added to each well and incubated at room temperature on a shaker at 
850 rpm for 30 min. Subsequently, 50 µL of streptavidin-PE was added to each well and incubated at 
room temperature in a shaker at 850 rpm for 10 min. After three washes, 125 µL assay buffer was 
added to each well and incubated at room temperature for 30 s. After incubating, the plates were read 
on the Bio-Plex® 200 system and analyzed by using in Bio-Plex Data ProTM Software (Gladesville, 
NSW, AUS). All the tests were performed in triplicate. 
2.7. Toxicity Assay Lactate Dehydrogenase (LDH) 
After incubation with the respective treatments, the supernatants were collected for the 
determination of cytotoxicity by using the lactate dehydrogenase (LDH) assay. The cellular 
cytotoxicity was assessed by the LDH in-vitro cytotoxicity assay (TOX7, Sigma-Aldrich, St. Louis, 
MO, USA). The culture supernatants were centrifuged at 250× g for 4 min. An aliquot containing 50 
µL of either blank (complete medium) or control (cells only) and cells treated with tunicamycin 
(TUN) supernatants obtained after the respective time point incubations was mixed with 100 µL of a 
solution containing the LDH assay mixture (LDH substrate, LDH dye, and LDH cofactor). The 
mixture was then incubated at room temperature for 20 to 30 min and the reaction was quenched by 
the addition of 1N hydrochloric acid (15 µL). The absorbance was measured spectro-photo-metrically 
by using a plate reader (Spectra Max M2 microplate reader, Sunnyvale, CA, USA) at a wavelength of 
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490 nm. The cellular viability was examined by a Trypan Blue exclusion staining assay using a 
Countess Automated Cell Counter (Thermo-Fisher, Waltham, MA, USA). 
2.8. Western Blot 
The cells (1 × 106 treated for 6 h) post treatments were washed with HBSS followed by 
homogenization in 2 mL of RIPA buffer/10% of Protease Inhibitor (Sigma-Aldrich, AUS). After 
subjecting to centrifugation at 12,000 rpm for 20 min at 4 °C, the supernatant was collected. Thirty 
micrograms of protein from each sample was denatured in Laemmli loading buffer (Bio-Rad 
Laboratories, AUS) and separated on precast 12% SDS-PAGE gels (Bio-Rad Laboratories, AUS), 
which was followed by overnight transfer onto Polyvinylidene difluoride (PVDF) membranes 
(Millipore, NSW, AUS) at 30 mV at 4 °C. By using 5% non-fat milk, the blot was blocked before 
incubating with respective antibodies: anti-GADPH, Survivin, Grp78 (#14C10, 1:3000, Novus 
Biologicals, AUS), poly(ADP-ribose)polymerase (PARP), and cleaved PARP (SIGMA, VIC, Aus) 
overnight at 4 °C in blocking buffer. The blot was washed in PBST and incubated with appropriate 
species monoclonal horseradish peroxidase-conjugated anti-IgG secondary antibodies (1:5000) for 1 
h at 20 °C. The bands were visualized by using the Supersignal West Pico chemi-luminescent kit 
(Thermo Scientific, VIC, AUS). It was digitized and the band intensities were determined by using a 
Fuji LAS-3000 Imager (Fuji Life Sciences, JPN). The samples from all groups were included in each 
individual blot to ensure accurate quantification across multiple blots. 
2.9. Apoptosis Assays 
2.9.1. Caspase-3 Assay 
The Caspase-3 fluorimetric test was performed on the cell lysates, which were collected after the 
6-h treatment as indicated by the guidelines, which gave the test unit and past reference. This 
compound test depended on the hydrolysis of the caspase-3 peptide substrate (acetyl-Asp-Glu-Val-
Asp or AC-DEVD) conjugated to a fluorochrome at the C-terminal Asp, which brings the arrival of 
the fluorescent moiety. After the fluorimetric treatment, the fluorescence (absolute units) was 
estimated by utilizing the CytoFluor Multi-Well Plate Reader Series 4000 spectro-fluorometer from 
PerSeptive Biosystems (Framingham, MA, USA) as per the manufacturer’s protocol. 
2.9.2. Annexin V Assay 
The Annexin-V-Fluos assay (cat. No. 11828681001, Roche Diagnostics, Zug Switzerland) was 
utilized to measure apoptotic (annexin V) cell populations. The cells after the 6 h treatments were 
incubated in incubation buffer (10 mM HEPES at pH 7.4, 140 mM NaCL, 2.5 mM CaCl2) and 
supplemented with annexin V–PI mix for 15min atroom temperature (RT) and the cells were 
analyzed by flow cytometry and confocal microscopy with 4′,6-diamidino-2-phenylindole(DAPI) as 
nuclear staining and the Fluorescein isothiocyanate (FITC) channel (fluorescein) for visualizing 
apoptosis cells (Nikon AR1MP) per the manufacturers’ protocol. 
2.10. Proliferation Assay 
The proliferation test 5-ethynyl-2′-deoxyuridine (EdU) (Invitrogen, VIC, Aus) was executed 
according to the guidelines included by the producer, which means the upgraded convention. The 
Click-iT™ EdUIF Assay Kit, Invitrogen™ was included at a 50 µM final concentration. After the 
respective treatments, the cells were subjected to 3 × 5 min PBS washes. A cell volume of 20–30 µL 
was directly incubated at room temperature (RT) in the EdU detection cocktail (Invitrogen, Click-
iTEdU Alexa Fluor 488 HCS assay, cat no: {“type”:“entrez-nucleotide”,“attrs”: 
{“text”:“A10027”,“term_id”:“492344”,“term_text”:“A10027”}} A10027) for 30 min. For a one sample 
reaction, the following amounts of the kit components are mixed in 144 µL distilled water: 1.6 µL 
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buffer additive (component F, kept frozen in small aliquots), 14 µL reaction buffer (Component D), 
6.7 µL Copper (II) sulfate solution (Component E, 100 mM CuSO4), and 0.07 µL Alexa Fluor 488 azide 
(Component B, in 70 µL DMSO). Confocal laser scanning microscopy was performed by using the 
Olympus Fluoview FV1000 confocal laser scanning microscope (Olympus Life Science Europa 
GmbH, Hamburg, Germany). Alexa Fluor 488 images were captured under excitation: 460–490 nm, 
dichroic beam splitter 505 nm, and emission of 510–550 nm. The images were analyzed by using 
ImageJ software (Madison, WI, USA). 
2.11. Statistical Analysis 
Statistical significance of the differences between groups among repeated experiments was 
calculated by one-way and two-way ANOVA and the Fisher's LSD-test using GraphPad Prism 7 
software (GraphPad Software Ltd, La Jolla, CA, USA). The results are expressed as the mean values 
± standard deviation. In all statistical tests, a p-value < 0.05 was considered statistically significant. 
3. Results 
3.1. Increased Survivin Expression in the Colon of Winnie 
We utilized the Winnie mouse model [13] of chronic ERS and control black 6 (Blk6) mice to assess 
the expression of Survivin in the colon since there was an increased ERS documented in the Winnie 
goblet cells. We have first checked the expression of Survivin in the colon tissue by 
immunohistochemistry (IHC) and immunofluorescence (IF). IHC revealed an increase in the 
expression of Survivin in the colonic epithelial cells, which is shown in Figure 1A,B. Similar to that 
of the IF where there was a striking elevated expression observed in Winnie compared to that of wild 
type mice where there was hardly any expression of Survivin (Figure 1C,D). We further isolated the 
goblet cells from the colons of both Winnie and Blk6 mice and performed IF analysis to precisely 
define the Survivin expression in the cells. There was a significant increase in the expression of 
Survivin in Winnie goblet cells compared to the wild type Blk6 (Figure 1E,F). We have also evaluated 
the Survivin protein expression of the goblet cells by using a Western blot where the Survivin protein 
expression of the goblet cells was found to increase in Winnie compared to the wild type mice (Figure 
1H). 
To further assess the functional relationship between Survivin and ERS, we employed an in vitro 
evaluation on a similar goblet cell like mucous secretory epithelial cell line (LS174T) to determine the 
functional and downstream effects of ERS induction and inhibition in the context of cancer and its 
emerging effects. 
3.2. Dynamics of Survivin in Line with Endoplasmic Reticular Stress (ERS) 
Having determined the expression of Survivin in Winnie goblet cells, we then investigated the 
dynamics in LS174T cells. First, to study the molecular dynamics of Survivin in parallel with ERS, we 
treated LS174T cells with TUN over a period of seven days and collected RNA at various time points 
(0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, and 7th day) to determine mRNA 
expression. Grp78 was used as a standard marker of ERS. The lactate dehydrogenase assay (LDH) 
was also performed at various time points to monitor the extent of cell death. It was evident from 
quantitative real-time PCR that the expression of Survivin was greatest (2.5-fold increase vs control) 
at 6 h (360 min) of TUN treatment and this increase in Survivin expression was concomitant with a 
similar increase in the ERS maker Grp78 (Figure 2A,B). The expression pattern of surviving showed 
a steady increase and reached the highest level by the sixth hour post TUN treatment. After the sixth 
hour time point, there was a steady drop in Survivin expression resulting in no expression by the 
900th minute (Figure 2A). Similar to Survivin expression, ERS induction by TUN showed an expected 
pattern of Grp78. 
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ERS-mediated cell death was shown through the LDH assay. There was no cell death recorded 
in the LDH assay during the sixth hour time point, which also proves that there was no death 
occurring during high ERS under TUN treatment. 
 
Figure 1. Expression of Survivin in Winnie. (A) Expression of Survivin in Winnie colon tissue. (B) 
Expression of Winnie in control black 6 (Blk6) colon tissue. (C) Double staining of Survivin in Winnie 
colon (Red-Survivin, Blue-4′,6-diamidino-2-phenylindole (DAPI)). (D) Double staining of Survivin in 
Blk6 colon (Red-Survivin, Blue-DAPI). (E) Representation of double staining of Survivin on colonic 
goblet cells of Winnie (violet- Survivin, blue-DAPI). (F) Representation of double staining of Survivin 
on colonic goblet cells of Blk6 (violet- Survivin, blue-DAPI). (G) Immunofluorescence (IF) 
quantification of Survivin expression in goblet cells. (H) Protein expression by Western blot for 
Survivin in the Winnie and Blk6 colonic goblet cells standardized by β-Actin. 
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Figure 2. Molecular dynamics of Survivin with respect to Endoplasmic Reticular Stress (ERS). (A) 
Molecular dynamics of Survivin in the LS174T cell line with ERS treatment by TUN 10 µg/mL. (B) 
mRNA dynamics release of Grp78 in the LS174T cell line with ERS treatment by TUN 10 µg/mL. (C) 
LDH assay of the LS174T cells with ERS treatment by TUN 10 µg/mL. 
3.3. Inhibition of Endoplasmic Reticular (ER) Stress Is Correlated to Survivin Expression in the LS174T Cell 
Line 
Having established the dynamics of Survivin expression under ERS conditioning, we further 
aimed to establish the relationship between Survivin, ERS, and the inhibition of apoptosis. 
Accordingly, the LS174T cells were incubated with an ERS inducer TUN (10 µg/mL) for 6 h since it 
was the time point in the previous assay with the highest ERS and the UPR genes (Grp78, XBP1, 
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PERK, and ATF6) were assessed. We observed an increase expression of UPR genes concomitant with 
an increase in Survivin expression. Upon treating with TUN, the expression of GRP78 rose to 35-fold, 
which was diminished under ERS inhibition by 4PBA (Figure 3A). The expression of PERK was 
dropped to two-fold in a 4PBA treated group compared to the TUN group, which was 25-fold 
increased (Figure 3C). A similar significant drop of UPR genes was observed in ATF6 where the 
expression was declined to two-fold in the 4PBA group in comparison to the TUN treated group, 
which was six-fold (Figure 3E). A significant expression of Survivin was reduced under ERS 
inhibition where the relative expression reduced to 1.25-fold from 0.31 (Figure 3B). There was no 
significant expression of XBP1 recorded in our study upon ERS induction by TUN. This was similar 
to the expression of IRE1 (Figure S1) which could be because of the regulation of XBP1 by IRE1 (Figure 
S2). We have then performed the Western blot analysis of the protein extract from the LS174T cells 
treated with TUN and 4PBA. There was a noticeable significant increase in protein expressions of 
both Survivin and Grp78 in the groups induced with ERS and a significant reduction in expressions 
of Grp78 and Survivin observed in groups under reduced ERS by 4PBA (Figure 3F–H). These results 
depict the relationship of ERS and the inhibition of apoptosis. 
 
Figure 3. Expression of UPR genes and Survivin modulated by ERS induction and inhibition. mRNA 
expression of UPR genes: (A) Grp78, (B) Survivin, (C) PERK, (D) XBP1, and (E) ATF6 in LS174T cells 
treated with TUN 10 µg/mL and 10 mM of 4PBA for 6hours normalized to GAPDH (n = 3). Data are 
shown as the mean fold change  ±  SEM (significance testing vs TUN: *, **, ***; p < 0.05, p <0 .01 and p 
< 0.001 respectively). (F) Representative Western blot for Survivin and Grp78. (G) Western blot 
quantification of Survivin. The bands were normalized with β-Actin and quantified. (H) 
Quantification of Western blot of Grp78. 
Since the ERS inhibition could reduce UPR markers and inhibition of apoptosis, we wanted to 
evaluate the effects of ERS reduction in ameliorating ERS mediated inflammation (Figure 4). 4PBA 
successfully modulated pro-inflammatory and anti-inflammatory cytokines in our study. TUN at a 
dose of 10 µg/mL could successfully induce ERS-mediated inflammation in LS174T cells evident 
through the up regulation of pro-inflammatory cytokines IL8, IL4, and IL6 from 584 ± 9.1, 573.52 ± 
15.84, and 2.11 ± 0.19 pg/mL to 1258.9 ± 59, 1996.84 ± 3.6, and 2.9 ± 0.1 pg/mL, respectively (p < 0.00001) 
(Figure 4). ERS inhibition by 4PBA significantly reduced the inflammatory cytokines to 507.1 ± 16.3, 
388.57 ± 10.61, and 2.2 ± 0.1 pg/mL, which offers a strong protection from inflammation (Figure 4). 
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The 4PBA and TUN group also offered significant protection against inflammation at 910.2 ± 30.12, 
1258.39 ± 89.6, and 1.89 ± 0.11 pg/mL (p < 0.001). The anti-inflammatory cytokine IL10 was also 
substantially modulated by inhibiting ERS. Upon inflammation, IL10 was standing at 3.0 ± 0.1 pg/mL 
and, after co-treatment with 4PBA, the value of IL10 rose to 13.7 ± 1.1 pg/mL alongside the combined 
group (4PBA and TUN) with a surprising 7.4 ± 0.6 pg/mL, which signifies that not only does ERS 
inhibition lead to reduction in pro-inflammatory cytokines but also regulates anti-inflammatory 
cytokines. 
 
Figure 4. Cytokine expression of (A) IL8, (B) IL10, (C) IL4, and (D) IL6 in LS174T cells treated with 
TUN 10 µg/mL TUN and 10 mM of 4PBA. (significance testing vs TUN: *, **, ***; p < 0.05, p < 0.01 and 
p < 0.001 respectively) 
3.4. Inhibition of ERS Escalates Apoptosis in Colon Cancer Cells 
To validate the induction of apoptosis with relation to TUN mediated effects, LS174T cells were 
subjected to ERS induction with 10 µg/mL TUN and ERS inhibition by 10 mM of 4PBA and apoptosis 
was quantified by staining with Annexin V (FITC). There was an increase of apoptosis in the cells 
treated with 4PBA alone when compared to TUN and cells alone groups. Cells treated with 4PBA 
alone also demonstrated a change in their morphology such as a disoriented nucleus when compared 
to the control group and TUN group (Figure 5D). There was a significant increased apoptosis 
recorded through the FITC flow cytometry where the apoptotic cells were plotted through the graph 
represented by the 4PBA group. There was a shift of cells from the live to the apoptotic column 
(Figure 5E) observed in the flow cytometry graph compared to the TUN where the live cell numbers 
were denoting a higher increased live cell number and higher control groups where the live cells 
were geared towards live and pre-apoptotic systems (Figure 5E). The cells were shifting to early 
apoptotic in the TUN+4PBA group and towards necrotic or late apoptotic systems in the 4PBA alone 
group. 
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Figure 5. The effect of ERS on apoptosis by the Annexin V assay. The Annexin V assay of LS174T cells 
treated with 10 µg/mL TUN and 10 mM of 4PBA for 6 h stained with Annexin V-FITC and analyzed 
by confocal microscopy. (A) Cells not subjected to any treatment (control). (B) Cells treated with TUN 
alone. (C) Cells treated with TUN + 4PBA. (D) Cells treated with 4PBA alone. The graphs represent 
the flow cytometry analysis after respective treatments. (E) Control group containing non-treated cells 
that were viable and not undergoing apoptosis. Cells treated with TUN and not prone to apoptosis. 
Cells treated with TUN + 4PBA, which have started shifting towards the apoptotic window (early 
apoptosis). Cells treated with 4PBA and in the end-stage apoptosis or already dead. Additionally, 
there was an increase in dead cell populations observed. (The axis of the flow cytometry is represented 
by PI (Propinium iodide and Annexin V. LA represents late apoptosis. NC represents necrotic. LC 
represents live cells and AP represents apoptotic). Scale bar represents 75 µm. 
To investigate the occurrence of programmed cell death due to Caspase activation, cell 
supernatants from the treated LS174T cells were subjected to the Caspase 3/7 assay. In this case, we 
have observed a significantly increased Caspase 3/7 expression in the 4PBA alone group compared 
to the 4PBA + TUN and TUN groups (Figure 6A). Parallel to this, the cleavage of PARP, which is an 
executioner Caspase substrate, was also detected by using Western blot analysis. The cleaved PARP 
(Figure 6B) was increased in the group treated with 4PBA (ERS inhibition), which suggests that 4PBA 
increases apoptosis partially through mitochondrial-mediated cell death and also that reducing the 
protein folding by 4PBA leads to the initiation of cell death. 
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Figure 6. Influence of ERS on Caspase3/7 and PARP cleavage assays. (A) Effect of Caspase3/7 assay 
on LS174T cells (control or non-treated, 4PBA at a concentration of 10 mM, TUN at a concentration of 
10 µg/mL and TUN + 4PBA). (B) Western blot of PARP and cleaved PARP of respective groups 
normalized with β-Actin. (significance testing vs TUN: *** p < 0.001 respectively) 
3.5. ERS Exhibits Direct Relationship to Proliferation in the LS174T Cell Line 
After evaluating the process of ERS inhibition, which leads to an increase in apoptosis, we 
decided to determine the cellular proliferation with regard to ERS inhibition and induction. The 5-
ethynyl-2′-deoxyuridine EdU assay for in-vitro proliferation was employed for this purpose. 
Following ERS induction and inhibition, the LS174T cells were seeded in eight chamber wells and 
incubated with an EdU click assay reagent and visualized through confocal microscopy. Images were 
quantified by Image J® software. We observed a reduction in cellular proliferation observed in 4PBA 
groups when compared to the TUN group where the proliferation was significantly increased (Figure 
7B) and when compared to the control group. Proliferation increased by TUN was almost 250-fold 
compared to the ERS inhibition groups (4PBA alone and 4PBA + TUN) where the proliferation rate 
dropped to 10-fold from 250 (Figure 7E). 
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Figure 7. The effect of ERS on the proliferation rate and Muc2 expression in LS174T cells. Cell 
proliferation assay performed by a 5-ethynyl-2′-deoxyuridine(EdU) click assay after incubating with 
treatments. (A) The cells alone or non-treated (B) TUN at a concentration of 10 µg/mL. (C) 4PBA at a 
dose of 10 mM. (D) TUN + 4PBA. (E) Quantification of the proliferation assay by Image J® representing 
different groups. (F) Muc2 gene expression (cells after treatments were subjected to RT-PCR). Scale 
bar represents 50 µm. (significance testing vs TUN: *** p < 0.001 respectively). 
We further correlated Muc2 gene expression with a proliferation rate under ERS. We performed 
RT-PCR for Muc2 expression with ERS induction and inhibition groups (Figure 7F). The data revealed 
the increased expression of Muc2 with the induction of ERS by 10 µg/mL TUN to 40-fold, which 
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denotes the relation of ERS and proliferation. ERS inhibition by 4PBA at a dose of 10 mM reduced 
the Muc2 expression significantly five-fold. A similar expression was noted in the TUN + 4PBA group. 
3.6. YM155, a Survivin Inhibitor, SubsidesERS and ERS Mediated Inflammation 
Since we could inhibit Survivin expression and inflammation under reduced ERS condition, we 
wanted to investigate whether we could show the converse effect of Survivin inhibition and its effect 
on ERS. Consistent with the ERS inhibition, Survivin inhibition by YM155 also resulted in the 
decrement of ERS markers both at the transcription and the protein level. We investigated the 
potential of Survivin inhibition in ameliorating ERS in the LS174T cell line. Exposure to TUN 10 
µg/mL resulted in a significant increase of the UPR genes along with Survivin. Upon treatment with 
YM155, the expression of Survivin as expected reduced from 3.2 fold to 1 fold (shown in Figure 8A). 
YM155 showed marked reduction of UPR genes like GRP78 from 30-fold to two-fold (Figure 8B). 
Additionally, 0.9-fold to 0.2-fold for XBP1 (Figure 8C) and a startling four-fold from 22-fold for PERK 
(Figure 8D) and a drop to 1.8-fold from eight-fold for ATF6 (Figure 8E). 
Similar responses were also observed in the cellular protein levels of Grp78 and Survivin as 
shown by Western blot analysis where Survivin inhibition also lead to ERS inhibition (Figure 8F–H), 
which confirms that modulation of mRNA expression is reflected in active protein suppression of 
Survivin and ERS through Grp78 as well. 
Functional inhibition of Survivin showed a striking change in inflammation in LS174T cells 
where YM155 modulated IL8, IL4, and IL6 (Figure 8I,J,L). The grounded levels of cytokines (584.48 ± 
9.7, 573.5 ± 15.8, and 2.11 ± 0.19 pg/mL) increased to 1258.39 ± 89.6, 1996.8 ± 13.42, and 2.9 ± 0.1 pg/mL. 
Upon treatment with YM155, there was a marked decrease in pro-inflammatory markers to 707.18 ± 
16.2, 1388.8 ± 10.38, and N.S pg/mL (p < 0.0001). There was also a positive variation in the anti-
inflammatory cytokine IL10 from 3.0 ± 0.1 to 9.7 ± 1.1 upon YM155 treatment shown in Figure 8J. 
Combined treatment of YM155 with TUN also exhibited significant activity where the cytokine levels 
were 910.27 ± 29.8, 1258.30 ± 13.10, and 1.89 ± 0.1 pg/mL (p < 0.0001). 
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Figure 8. Gene expressions of UPR genes, Survivin, and measurement of inflammatory cytokines of 
cells treated with YM155.mRNA expression of UPR genes: (A) IAP gene Survivin, (B) Grp78, (C) 
XBP1, (D) PERK, and (E) ATF6 in LS174T cells treated with TUN 10 µg/mL and 100 nM of YM155 for 
6hours normalized to GAPDH (n = 3).The data are shown as the mean fold change ± SEM (significance 
testing vs TUN: *, **, ***; p < 0.05, p < 0.01, and p < 0.001, respectively). (F) Representative Western blot 
for Survivin and Grp78. The bands were normalized with β-Actin and quantified. (G,H) represents 
Western blot quantification. Cytokine expression of (I) IL8, (J) IL10, (K) IL4, and (L) IL6 in LS174T 
cells treated with TUN 10 µg/mL and 100 nM of YM155. 
3.7. YM155 Initiates Cell Death in LS174T Cells via Caspase3/7 
As IAPs target the Caspase pathways specifically, we wanted to evaluate whether Survivin 
inhibition by YM155 could elevate Caspase 3/7. Figure 9 presents the effect of YM155, which, at a 
concentration of 100 nM, increased the expression of Caspase 3/7 significantly when compared to the 
TUN group and also the control group. The YM155 + TUN group also induced Caspase 3/7 activity. 
This clearly confirms that Survivin inhibition may lead to cancer cell apoptosis in the intrinsic death 
pathway. 
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Figure 9. The effect of Survivin inhibition on Caspase 3/7 assay.LS174T cells were treated with YM155 
for 6 h and apoptosis was determined by the Caspase 3/7 assay representing the following 
groups:control or non-treated, YM155 at a concentration of 100 nM, TUN at a concentration of 10 
µg/mL, and TUN + YM155. 
4. Discussion 
Our study provides evidence that ERS mediated signaling pathways are one of the major 
protective mechanisms adopted by cancer cells where they inhibit the ERS responses including 
apoptosis. We have described the role of Survivin in the above described mechanism. In the present 
study, we have demonstrated the effects of ERS inhibition by 4PBA over reduction of UPR markers 
and also Survivin. We have also enumerated that ERS inhibition leads to amelioration of ERS 
mediated inflammation, increases apoptosis in LS174T cells, and lessens cancer cell proliferation. 
First, in order to validate the expression of Survivin in vivo, we determined the expression of Survivin 
in the colon tissue and goblet cells isolated from Winnie, which is a chronic model of severe ERS. We 
noticed that Survivin expression was elevated compared to the wild type, which presents a similar 
trend to that of previous studies on colon cancer [16,19]. This prompted us to further investigate 
goblet cell like Muc2 expressing the cell line LS174T for linking between Survivin and ERS. Even 
thoughJayakumar et al. has explored the molecular dynamics of Survivin recently in cancer cells [20], 
the expression dynamics was not described with regard to ERS induced by chemical agents such as 
TUN. The 6th hour time point, which was regarded as the highest expression of Survivin, along with 
Grp78 identified this as the end time point for all the experiments in our studies into the path of ERS-
mediated apoptosis. 
It is well established that ERS leads to pathogenesis of numerous diseases including cancer. The 
ERS aids in the adaptation against non-favorable conditions and is involved in tumor growth. The 
UPR markers namely IRE1, XBP1, PERK, and Grp78 are involved in tumorigenesis [21]. ER resident 
chaperones including calreticulin lowered cell death and have been associated with ERS induction in 
tumor cells [21]. TUN at a dose of 10µg was able to increase the expression of UPR genes (Grp78, 
PERK, XBP1, and ATF6) and IAP protein Survivin, which indicates the role of ERS in tumor 
promotion. Likewise, 4PBA reduced the expression of all ERS markers (UPR genes) alongside the 
expression of Survivin, which denotes that ERS inhibition leads to Survivin reduction. We have 
additionally evaluated the potential of ERS inhibitor 4PBA in ameliorating the ERS mediated 
inflammation induced by TUN. In recent studies, 4PBA was employed to ameliorate LPS-induced 
lung inflammation through modulation of the NF-κB/IκB and HIF-1αsignaling pathways, which 
highlights the benefit of reducing ERS [22]. 
There is a mounting evidence involving cytokines such as IL8, IL4, and IL6 in inflammation 
mediated carcinogenesis. IL8 expression correlates with the angiogenesis, tumorigenicity, and 
metastasis of tumors in numerous xenograft and orthotopic in vivo models [23]. IL8 in association 
with CXCR1 was related to a high prognosis of human pancreatic cancer [24]. 4PBA 
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exhibitedareduction of IL-8 significantly when compared to the TUN group in our study and suggests 
that ERS inhibition may lead to reduced tumorigenesis. As stated earlier, interleukins are involved 
in growth, differentiation, and migration in various cancers. Apart from decreasing apoptosis in cell 
lines such as HCT116 [25], IL4Rα contributed to tumor formation in a mouse model of colitis-
associated cancer and mediated proliferation of epithelial tumor cells [25]. Previous studies indicated 
efficacious treatment against cancer due to the blockade of IL4 where the functional role of IL4 
cytokine was demonstrated as an important mechanism that protects the tumorigenic CD133+ cells 
from apoptosis [26]. Similar to the above mentioned description, our data also demonstrated a role 
of IL4 in TUN mediated inflammation. We aimed to observe the effects of ERS inhibition by 4PBA 
over IL4 in TUN-mediated inflammation where we observed a significant reduction of IL4 levels in 
the groups (4PBA and 4PBA + TUN), which was in line with previous findings where the blocking of 
IL4 signaling sensitized cancer stem cells (CSCs) to apoptotic stimuli and increased the in vivo 
efficacy of cytotoxic therapy [27]. Additionally, in colon cancer stem cells, Survivin was regulated by 
IL4 through STAT-6 signaling and allowscancer cells to escape chemo sensitizing [28], which can be 
explained through our study that ERS inhibition may have reduced Survivin expression via IL4. The 
fact that the ERS inhibition in our study with 4PBA led to IL-10 elevation was a significant finding 
because IL10 stimulated cytotoxicity in CD8+ cells and cancer cells treated with pegylated IL-10 led 
to tumor rejection, anti-tumor effects, and tumor-associated inflammation [29]. It was also notable 
that IL10−/− mice were found to be particularly susceptible to chemically induced skin cancers, which 
highlights its protective role. IL10 along with PD-1 exhibited an anti-tumor response in ID8 ovarian 
tumor bearing mice, which leads to a decrease in tumor mass and a significant increase in survival 
[30]. Lastly, IL6 evaluated in our study was previously related to an advanced stage of CRC 
development [31] where it was proved that IL6 promoted tumor cell proliferation and inhibited 
apoptosis through gp130 activation. IL6 levels not only increased in patients but also in the tumor. 
The same study reported that IL-6 levels greatly determined patient survival. IL6 was one of the 
cytokines, which was linked directly between IBD and CRC [31]. 4PBA in our study reduced the 
expression of IL-6 along with other inflammatory cytokines, which can be related to previous studies 
of attenuation of angiogenesis and tumor formation in colon cancer [32]. 
UPR mediators are regarded as being fundamental to ERS-mediated apoptosis [33]. Knocking 
down of Grp78 in tumor-associated endothelial cells led to an increase in apoptosis, which reveals 
that ER chaperone inhibition would result in reducing carcinogenesis [34]. The evaluation of early 
apoptosis was carried out by Annexin V flowcytometry and IF assays where it was evident that the 
ERS inhibition by 4PBA leads to significant apoptosis induction. Programmed cell death is an 
important mechanism that leads to collateral destruction of cancer cells with occasional killing of 
normal cells and without an inflammatory response, which leads to the maintenance of proper 
homeostasis. Therefore, an apoptosis-inducing compound is beneficial as a useful chemotherapeutic 
agent against carcinogenic effects [35]. The ERS inhibition (4PBA alone) exhibited early apoptosis, 
which was evident by immune fluorescence and also the flow cytometry where the cell population 
was shifted from viable to apoptotic in the 4PBA alone treated group. This is comparable to a previous 
study by Kwan et al. on MCF-7 breast cancer cells [36]. 
Although Caspase 9 is a trigger of the intrinsic death pathway, Caspases 3 and 7 are regarded as 
the major effectors for apoptosis execution [36]. There are numerous roles played by Caspase 3 
including apoptosis-associated chromatin margination and DNA fragmentation [37]. Our results 
showed that the concentration-dependent 4PBA increasedcaspase-3/7 activity in LS174T cells, which 
suggests that ERS inhibition by 4PBA-induced apoptosis is a Caspase-dependent mechanism (Figure 
10), as induced in a previous study where the breast cancer cells were treated by plant extracts [38]. 
PARP activation and subsequent cleavage play a major role in programmed cell death [39]. 4PBA 
via ERS inhibition in our study could induce the cleavage of PARP, which is regarded as the hallmark 
of apoptosis [40]. Previous similar studies have reported a similar condition of calcium-dependent 
protease and calpain being activated in various models of apoptotic cell death, which results in 
atypical PARP cleavage [41]. Cancer cells standout from normal cells in aspects such as being 
proliferative, being anaerobic, and creating a microenvironment that is deprived of nutrients, which 
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makes them resistant to cancer therapy [42]. This microenvironment also triggers ERS leading to 
apoptosis, but cancer cells have adapted themselves against the UPR alterations to avoid cell death. 
In our study, we have unraveled the connection between the changes in UPR and proliferation. The 
ERS induced by TUN escalated the proliferation rate in our study similar to a previous study where
bleomycin activated ER stress-associated proteins including Grp78, CHOP, and ATF-4 both in vitro 
and in vivo, which increased the lung fibroblast proliferation via upstream activation of ERS by 
PI3K/AKT [43]. 4PBA could markedly reduce the proliferation rate (4PBA alone and 4PBA+TUN). 
The surprising decrease of proliferation by ERS inhibition paves the way for the therapeutic potential. 
UPR activation can enable cancer cells to survive and adapt to harsh environments, which indicates 
the example of ER stress being a key secondary event in melanoma development and which 
contributes to the resistance of apoptosis through the persistent expression of pro-survival instead of 
pro-apoptotic proteins [44]. It was no surprise that the sixth hour time point had the highest 
proliferation recorded where the rate of relative expression of Grp78 and Survivin was the highest. 
The levels of Mucin2 (Muc2) is highly controversial in cancers especially colon and colorectal cancers. 
Patients with advanced mucinous colorectal carcinomas had a strong expression of Muc2 with 
increased metastasis [45] and it has been correlated with another proliferative protein known as 
Galectin-3, which is highly involved in migration and survival. Muc2 levels in the TUN-treated group 
skyrocketed when compared to the treated groups (4PBA and 4PBA+TUN). These treated groups 
were similarly shown in a study by Lakshmanan et al. where mucins were associated with poor 
prognosis in terms of lung cancer [46] and Muc2 over-expression was found to be an independent 
prognostic factor for ovarian cancer patients [47]. ERS reduction significantly curtailed the Muc2 
expression, which indicated a clear anti-proliferative potential observed in our study. 
 
Figure 10. Mechanism and role of 4PBA and YM155. (A) 4PBA. (B) YM155.ERS is a distress signal 
triggered due to accumulation of misfolded proteins in the ER. 4PBA (A), which is an ERS inhibitor 
in our study, played a role in inhibiting the UPR genes by acting as an agent and by reducing the 
protein misfolding in the ER and also aiding in apoptosis via cytochrome-c release. The post-apoptotic 
signaling, Survivin, is released from the mitochondria block cytochrome-c and inhibits the Caspases, 
which inhibits programmed cell death. (B) YM155, which is a Survivin inhibitor, was found to escalate 
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apoptosis via the caspase3/7 pathway and aiding the free flow release of Caspases and facilitating cell 
death. 
YM155 was proved to act as metastasis antagonism in a mouse model of triple negative breast 
cancer [48]. YM155 was also utilized in a single-center study alongside docetaxel in patients with 
advanced hormone refractory prostate cancer and other tumors showed a partial positive response. 
A similar response was observed in patients with melanoma [49]. We initially assayed the effects of 
YM155 on LS174T cells treated with TUN and YM155 alone and noticed that YM155 could reduce the 
gene expression and protein expression of UPR genes in parallel to reducing Survivin expression 
along with the reduction in pro-inflammatory markers such asIL8 and IL4. Wagner et al. have 
revealed that YM155 played a pivotal role in reducing STAT3 signaling and UPR and was also used 
in the clinical evaluation of YM155 in patients with multiple myeloma [50]. There is a major regulation 
of apoptotic cell death by Caspases especially downstream Caspases such as 3 and 7. IAP proteins 
such as Survivin apart from controlling the Caspase activation platform also aid in cell survival via 
NF-κB signaling [51]. In line with previous findings by Wagner et al. where they have shown the pro-
apoptotic potential of YM155 on myeloma cells [50] and head neck squamous cell carcinoma tissues 
[52], we found that YM155 could elevate the levels of Caspase 3/7 in the LS174T cell line in both the 
TUN and YM155 alone groups (Figure 10). With our findings, we can attest 4PBA and YM155 as 
therapeutic agents in colorectal cancer via ERS mediated effects. It would be appropriate to evaluate 
the above effects in a mouse model of colorectal cancer and observe the downstream effects. 
5. Conclusions 
In conclusions, this study, for the first time, unfolds the interconnection between ERS and 
Survivin and proves that they are directly related and reciprocate effects like apoptosis and 
inflammation. The study has also exposed that ERS induction has a negative effect including 
worsening of carcinogenicity and proliferation while inhibition has a profound effect on apoptosis 
enhancement and proliferation reduction in LS174T cells by 4PBA and YM155, which clearly depicts 
a therapeutic scope. We have also revealed that Survivin is a key molecule that links ERS and 
apoptosis. 
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expression of IRE1, FigureS2: Pathway representing IRE1 orchestrating XBP1. 
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